Chalfont St. Giles, England and Menlo Park, CA 6/30/09; Cambridgeshire, UK 6/25/09—GE Healthcare has entered into an exclusive license and alliance agreement with biopharmaceutical firm Geron to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening. GE has licensed Geron’s intellectual property […]
Bridgewater, NJ 6/30/09; Carlsbad, CA 6/30/09—LabVantage Solutions, developer of the SAPPHIRE LIMS, has agreed to acquire the SQL*LIMS business from Applied Biosystems, a unit of Life Technologies, for an undisclosed amount. The SQL*LIMS is an enterprise LIMS. LabVantage will continue to support SQL*LIMS product and customers. “While the LIMS business is an important asset for […]
Productivity growth for 22 major publicly held laboratory instrument and product companies (see table, page 3) more than doubled in fiscal 2008. Productivity for the companies, as measured by average sales in US dollars per employee, increased 10.1%, up from a 5.4% growth in fiscal 2007, according to IBO’s analysis. Excluding the eight companies for […]
GE Healthcare and Geron announced this week that they are partnering to offer human embryonic stem cell (hESC)-derived assays for drug development and screening toxicity (see page 2). HESC-derived cell-based assays promise to supplement in vivo animal and in vitro cell testing for drug development. Applications could include target identification and validation, screening of compound […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
